Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | HTR2A | P28223 | 1/20 | 0.58 |
| ▸ | CPB1 | P15086 | 1/20 | 0.58 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.56 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL463641 | 0.89 | MGLL (0.54) | MGLLKMT2AMEN1HTR2ACPB1 | |
| SCHEMBL4500340 | 0.86 | MGLL (0.57) | MGLLKMT2AMEN1HTR2ACPB1 | |
| SCHEMBL13657578 | 0.84 | MGLL (0.71) | MGLLKMT2AMEN1HSD11B1 | |
| SCHEMBL18428493 | 0.82 | HTR2A (0.56) | MGLLKMT2AMEN1HTR2ACPB1 | |
| SCHEMBL324342 | 0.82 | HTR2A (0.56) | MGLLKMT2AMEN1HTR2ACPB1 | |
| SCHEMBL2552838 | 0.81 | HTR2A (0.62) | MGLLKMT2AMEN1HTR2ACPB1 | |
| SCHEMBL11398586 | 0.81 | HTR2A (0.58) | MGLLKMT2AMEN1HTR2ACPB1 | |
| SCHEMBL2556107 | 0.81 | CPB1 (0.67) | MGLLKMT2AMEN1HTR2ACPB1 | |
| SCHEMBL1720183 | 0.80 | MGLL (0.82) | MGLLKMT2AMEN1CPB1HSD11B1 | |
| SCHEMBL4500344 | 0.80 | HTR2A (0.56) | MGLLKMT2AMEN1HTR2ACPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| WO-2008011130-A2 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | DGAT2, DGAT1, DLAT | MGLL 387/4885KMT2A 667/4885MEN1 4411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.